From genetic abnormality to metastases: Murine models of breast cancer and their use in the development of anticancer therapies

Breast Cancer Research and Treatment

Volumn 96, Issue 2, 2006, Pages 101-113

  Ottewell, P D ^a   Coleman, R E ^a   Holen, I ^a  

^a UNIVERSITY OF SHEFFIELD   (United Kingdom)

Author keywords

Breast cancer; In vivo models; Metastases

Indexed keywords

4 HYDROPEROXYCYCLOPHOSPHAMIDE; 7 ETHYL 10 HYDROXYCAMPTOTHECIN; AE 941; ANTIESTROGEN; BEXAROTENE; BISPHOSPHONIC ACID DERIVATIVE; CISPLATIN; CYCLIN D1; DOXORUBICIN; FLUOROURACIL; FUMAGILLOL; IBANDRONIC ACID; MINODRONIC ACID; MYC PROTEIN; N(G) NITROARGININE METHYL ESTER; NITRIC OXIDE SYNTHASE INHIBITOR; PACLITAXEL; RISEDRONIC ACID; SEOCALCITOL; TACALCITOL; TAMOXIFEN; TISSUE INHIBITOR OF METALLOPROTEINASE 2; TOPOTECAN; TUMOR VACCINE; VIRUS T ANTIGEN; WNT1 PROTEIN;

ANALYTIC METHOD; BONE METASTASIS; BREAST CANCER; CANCER GROWTH; CANCER MODEL; CANCER THERAPY; CANCER TRANSPLANTATION; DISEASE COURSE; GENE; GENE MUTATION; GENETIC DISORDER; GENETIC ENGINEERING; IMMUNE DEFICIENCY; ISOGRAFT; METASTASIS; NONHUMAN; NUDE MOUSE; ONCOGENE C MYC; ORTHOTOPIC TRANSPLANTATION; OSTEOLYSIS; PATHOGENESIS; PHENOTYPE; PRIORITY JOURNAL; RETROVIRUS; REVIEW; SIMIAN VIRUS 40; TRANSGENIC MOUSE; TUMOR; TUMOR XENOGRAFT;

ANIMALS; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; CELL TRANSFORMATION, NEOPLASTIC; DISEASE MODELS, ANIMAL; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MAMMARY NEOPLASMS, EXPERIMENTAL; MICE; MICE, TRANSGENIC; NEOPLASM METASTASIS;

EID: 33645222400     PISSN: 01676806     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10549-005-9067-x     Document Type: Review

References (119)

1. Nathanson KL, Wooster R, Weber BL: Breast cancer genetics: what we know and what we need. Nat Med 7(5): 552-556, 2001
2. Nicoletto MO, Donach M, De Nicolo A, Artioli G, Banna G, Monfardini S: BRCA-1 and BRCA-2 mutations as prognostic factors in clinical practice and genetic counselling. Cancer Treat Rev 27(5): 295-304, 2001
3. Lichtenstein P, Holm NV, Verkasalo PK, Iliadou A, Kaprio J, Koskenvuo M, Pukkala E, Skytthe A, Hemminki K: Environmental and heritable factors in the causation of cancer - analyses of cohorts of twins from Sweden, Denmark, and Finland. N Engl J Med 343(2): 78-85, 2000
4. Bieche I, Lidereau R: Genetic alterations in breast cancer. Genes Chromosomes Cancer 14(4): 227-251, 1995
5. Cameron DA, Gregory WM, Bowman A, Anderson ED, Levack P, Forouhi P, Leonard RC: Identification of long-term survivors in primary breast cancer by dynamic modelling of tumour response. Br J Cancer 83(1): 98-103, 2000
6. Thiery JP: Epithelial-mesenchymal transitions in tumour progression. Nat Rev Cancer 2(6): 442-454, 2002
7. Gotzmann J, Mikula M, Eger A, Schulte-Hermann R, Foisner R, Beug H, Mikulits W: Molecular aspects of epithelial cell plasticity: implications for local tumor invasion and metastasis. Mutat Res 566(1): 9-20, 2004
8. Zlotnik A: Chemokines in neoplastic progression. Semin Cancer Biol 14(3): 181-185, 2004
9. Fidler IJ: Selection of successive tumour lines for metastasis. Nat New Biol 242(118): 148-149, 1973
10. Rudland PS, Fernig DG, Smith JA: Growth factors and their receptors in neoplastic mammary glands. Biomed Pharmacother 49(9): 389-399, 1995
11. Chirgwin JM, Guise TA: Interactions between tumor and bone alter the phenotypes of both. J Musculoskelet Neuronal Interact 3(4): 278-281, 2003 discussion 292-274
12. Chirgwin JM, Mohammad KS, Guise TA: Tumor-bone cellular interactions in skeletal metastases. J Musculoskelet Neuronal Interact 4(3): 308-318, 2004
13. Mundy GR: Metastasis to bone: causes, consequences and therapeutic opportunities. Nat Rev Cancer 2(8): 584-593, 2002
14. Body JJ: Metastatic bone disease: clinical and therapeutic aspects. Bone 13(Suppl 1): S57-S62, 1992
15. Guise TA, Mundy GR: Cancer and bone. Endocr Rev 19(1): 18-54, 1998
16. Fargiano AA, Desai KV, Green JE: Interrogating mouse mammary cancer models: insights from gene expression profiling. J Mammary Gland Biol Neoplasia 8(3): 321-334, 2003
17. Guise TA, Kozlow WM, Heras-Herzig A, Padalecki SS, Yin JJ, Chirgwin JM: Molecular mechanisms of breast cancer metastases to bone. Clin Breast Cancer 5(Suppl 2): S46-S53, 2005
18. Wagner KU: Models of breast cancer: quo vadis, animal modeling? Breast Cancer Res 6(1): 31-38, 2004
19. Bennett LM, McAllister KA, Malphurs J, Ward T, Collins NK, Seely JC, Gowen LC, Koller BH, Davis BJ, Wiseman RW: Mice heterozygous for a Brca1 or Brca2 mutation display distinct mammary gland and ovarian phenotypes in response to diethylstilbestrol. Cancer Res 60(13): 3461-3469, 2000
20. Liu B, Wang Y, Melana SM, Pelisson I, Najfeld V, Holland JF, Pogo BG: Identification of a proviral structure in human breast cancer. Cancer Res 61(4): 1754-1759, 2001
21. Rosol TJ, Tannehill-Gregg SH, LeRoy BE, Mandl S, Contag CH: Animal models of bone metastasis. Cancer 97(3 Suppl): 748-757, 2003
22. Nadon NL, Doersen CJ, Lade DA, Medina K, Thompson L, Rohrer M, Gimble JM: Multiple cellular phenotypes in an insertional mutation in mouse affecting bone development. Calcif Tissue Int 67(6): 449-454, 2000
23. Gravekamp C, Sypniewska R, Gauntt S, Tarango M, Price P, Reddick R: Behavior of metastatic and nonmetastatic breast tumors in old mice. Exp Biol Med (Maywood) 229(7): 665-675, 2004
24. Tarin D, McKinnell RG, Nace GW: Artificially induced metastasis by cells from spontaneous Lucke renal adenocarcinoma. Invasion Metastasis 4(4): 198-208, 1984
25. Michigami T, Hiraga T, Williams PJ, Niewolna M, Nishimura R, Mundy GR, Yoneda T: The effect of the bisphosphonate ibandronate on breast cancer metastasis to visceral organs. Breast Cancer Res Treat 75(3): 249-258, 2002
26. Mundy GR, Yoneda T, Hiraga T: Preclinical studies with zoledronic acid and other bisphosphonates: impact on the bone microenvironment. Semin Oncol 28(2 Suppl 6): 35-44, 2001
27. Sypniewska RK, Hoflack L, Tarango M, Gauntt S, Leal BZ, Reddick RL, Gravekamp C: Prevention of metastases with a Mage-b DNA vaccine in a mouse breast tumor model: potential for breast cancer therapy. Breast Cancer Res Treat 91(1): 19-28, 2005
28. Sloan EK, Stanley KL, Anderson RL: Caveolin-1 inhibits breast cancer growth and metastasis. Oncogene 23(47): 7893-7897, 2004
29. Hahn WC, Weinberg RA: Modelling the molecular circuitry of cancer. Nat Rev Cancer 2(5): 331-341, 2002
30. Arguello F, Baggs RB, Frantz CN: A murine model of experimental metastasis to bone and bone marrow. Cancer Res 48(23): 6876-6881, 1988
31. Minn AJ, Kang Y, Serganova I, Gupta GP, Giri DD, Doubrovin M, Ponomarev V, Gerald WL, Blasberg R, Massague J: Distinct organ-specific metastatic potential of individual breast cancer cells and primary tumors. J Clin Invest 115(1): 44-55, 2005
32. Yoneda T, Michigami T, Yi B, Williams PJ, Niewolna M, Hiraga T: Use of bisphosphonates for the treatment of bone metastasis in experimental animal models. Cancer Treat Rev 25(5): 293-299, 1999
33. Paget S: The distribution of secondary growths in cancer of the breast. Cancer Metastasis Rev 8(2): 98-101, 1989
34. Yoneda T, Michigami T, Yi B, Williams PJ, Niewolna M, Hiraga T: Actions of bisphosphonate on bone metastasis in animal models of breast carcinoma. Cancer 88(12 Suppl): 2979-2988, 2000
35. Yoneda T, Sasaki A, Dunstan C, Williams PJ, Bauss F, De Clerck YA, Mundy GR: Inhibition of osteolytic bone metastasis of breast cancer by combined treatment with the bisphosphonate ibandronate and tissue inhibitor of the matrix metalloproteinase-2. J Clin Invest 99(10): 2509-2517, 1997
36. Zhang J, Dai J, Qi Y, Lin DL, Smith P, Strayhorn C, Mizokami A, Fu Z, Westman J, Keller ET: Osteoprotegerin inhibits prostate cancer-induced osteoclastogenesis and prevents prostate tumor growth in the bone. J Clin Invest 107(10): 1235-1244, 2001
37. Sasaki A, Boyce BF, Story B, Wright KR, Chapman M, Boyce R, Mundy GR, Yoneda T: Bisphosphonate risedronate reduces metastatic human breast cancer burden in bone in nude mice. Cancer Res 55(16): 3551-3557, 1995
38. Sasaki A, Kitamura K, Alcalde RE, Tanaka T, Suzuki A, Etoh Y, Matsumura T: Effect of a newly developed bisphosphonate, YH529, on osteolytic bone metastases in nude mice. Int J Cancer 77(2): 279-285, 1998
39. Iwasaki T, Higashiyama M, Kuriyama K, Sasaki A, Mukai M, Shinkai K, Horai T, Matsuda H, Akedo H: NG-nitro-L-arginine methyl ester inhibits bone metastasis after modified intracardiac injection of human breast cancer cells in a nude mouse model. Jpn J Cancer Res 88(9): 861-866, 1997
40. Sargent NS, Oestreicher M, Haidvogl H, Madnick HM, Burger MM: Growth regulation of cancer metastases by their host organ. Proc Natl Acad Sci USA 85(19): 7251-7255, 1988
41. Weber MH, Lee J, Orr FW: The effect of Neovastat (AE-941) on an experimental metastatic bone tumor model. Int J Oncol 20(2): 299-303, 2002
42. El Abdaimi K, Dion N, Papavasiliou V, Cardinal PE, Binderup L, Goltzman D, Ste-Marie LG, Kremer R: The vitamin D analogue EB 1089 prevents skeletal metastasis and prolongs survival time in nude mice transplanted with human breast cancer cells. Cancer Res 60(16): 4412-4418, 2000
43. Kang MK, Kameta A, Shin KH, Baluda MA, Kim HR, Park NH: Senescence-associated genes in normal human oral keratinocytes. Exp Cell Res 287(2): 272-281, 2003
44. Ozzello L, Sordat B, Merenda C, Carrel S, Hurlimann J, Mach JP: Transplantation of a human mammary carcinoma cell line (BT 20) into nude mice. J Natl Cancer Inst 52(5): 1669-1672, 1974
45. Ozzello L, Sordat M: Behavior of tumors produced by transplantation of human mammary cell lines in athymic nude mice. Eur J Cancer 16(4): 553-559, 1980
46. Welsh J: Vitamin D compounds as potential therapeutics for estrogen-independent breast cancer. Nutrition 13(10): 915-917, 1997
47. Bao L, Jaligam V, Zhang XY, Kutner RH, Kantrow SP, Reiser J: Stable transgene expression in tumors and metastases after transduction with lentiviral vectors based on human immunodeficiency virus type 1. Hum Gene Ther 15(5): 445-456, 2004
48. Jenkins DE, Hornig YS, Oei Y, Dusich J, Purchio T: Bioluminescent human breast cancer cell lines that permit rapid and sensitive in vivo detection of mammary tumors and multiple metastases in immune deficient mice. Breast Cancer Res 7(4): R444-R454, 2005
49. Li X, Wang J, An Z, Yang M, Baranov E, Jiang P, Sun F, Moossa AR, Hoffman RM: Optically imageable metastatic model of human breast cancer. Clin Exp Metastasis 19(4): 347-350, 2002
50. Hoffman RM: Orthotopic metastatic mouse models for anticancer drug discovery and evaluation: a bridge to the clinic. Invest New Drugs 17(4): 343-359, 1999
51. Daoud SS, Leathers CW, Hurst JM: p53 expression, growth, and spontaneous metastasis of the human GI 101 breast carcinoma in athymic nude mice. J Exp Ther Oncol 2(2): 121-127, 2002
52. Maillard S, Ameller T, Gauduchon J, Gougelet A, Gouilleux F, Legrand P, Marsaud V, Fattal E, Sola B, Renoir JM: Innovative drug delivery nanosystems improve the anti-tumor activity in vitro and in vivo of anti-estrogens in human breast cancer and multiple myeloma. J Steroid Biochem Mol Biol 94(1-3): 111-121, 2005
53. Moon EY, Seong SK, Jung SH, Lee M, Lee DK, Rhee DK, Pyo S, Yoon SJ: Antitumor activity of 4-phenyl-1-arylsulfonylimidazolidinone, DW2143. Cancer Lett 140(1-2): 177-187, 1999
54. Zinser GM, Tribble E, Valrance M, Urben CM, Knutson JC, Mazess RB, Strugnell SA, Welsh J: 1,24(S)-dihydroxyvitamin D2, an endogenous vitamin D2 metabolite, inhibits growth of breast cancer cells and tumors. Anticancer Res 25(1A): 235-241, 2005
55. Boucharaba A, Serre CM, Gres S, Saulnier-Blache JS, Bordet JC, Guglielmi J, Clezardin P, Peyruchaud O: Platelet-derived lysophosphatidic acid supports the progression of osteolytic bone metastases in breast cancer. J Clin Invest 114(12): 1714-1725, 2004
56. Miller FR: Xenograft models of premalignant breast disease. J Mammary Gland Biol Neoplasia 5(4): 379-391, 2000
57. Flowers JL, Hoffman RM, Driscoll TA, Wall ME, Wani MC, Manikumar G, Friedman HS, Dewhirst M, Colvin OM, Adams DJ: The activity of camptothecin analogues is enhanced in histocultures of human tumors and human tumor xenografts by modulation of extracellular pH. Cancer Chemother Pharmacol 52(3): 253-261, 2003
58. Beckhove P, Schutz F, Diel IJ, Solomayer EF, Bastert G, Foerster J, Feuerer M, Bai L, Sinn HP, Umansky V, et al.: Efficient engraftment of human primary breast cancer transplants in nonconditioned NOD/Scid mice. Int J Cancer 105(4): 444-453, 2003
59. Chan WS, Page CM, Maclellan JR, Turner GA: The growth and metastasis of four commonly used tumour lines implanted into eight different sites: evidence for site and tumour effects. Clin Exp Metastasis 6(3): 233-244, 1988
60. Juacaba SF, Horak E, Price JE, Tarin D: Tumor cell dissemination patterns and metastasis of murine mammary carcinoma. Cancer Res 49(3): 570-575, 1989
61. Potter KM, Juacaba SF, Price JE, Tarin D: Observations on organ distribution of fluorescein-labelled tumour cells released intravascularly. Invasion Metastasis 3(4): 221-233, 1983
62. Kawaguchi T, Nakamura K: [Cancer metastasis and blood vessels]. Gan To Kagaku Ryoho 10(7): 1569-1576, 1983
63. Miner KM, Kawaguchi T, Uba GW, Nicolson GL: Clonal drift of cell surface, melanogenic, and experimental metastatic properties of in vivo-selected, brain meninges-colonizing murine B16 melanoma. Cancer Res 42(11): 4631-4638, 1982
64. Chambers AF, Tuck AB: Oncogene transformation and the metastatic phenotype. Anticancer Res 8(5A): 861-871, 1988
65. Nicolson GL, Belloni PN, Tressler RJ, Dulski K, Inoue T, Cavanaugh PG: Adhesive, invasive, and growth properties of selected metastatic variants of a murine large-cell lymphoma. Invasion Metastasis 9(2): 102-116, 1989
66. Pecheur I, Peyruchaud O, Serre CM, Guglielmi J, Voland C, Bourre F, Margue C, Cohen-Solal M, Buffet A, Kieffer N, et al.: Integrin alpha(v)beta3 expression confers on tumor cells a greater propensity to metastasize to bone. FASEB J 16(10): 1266-1268, 2002
67. Cardiff RD, Anver MR, Gusterson BA, Hennighausen L, Jensen RA, Merino MJ, Rehm S, Russo J, Tavassoli FA, Wakefield LM, et al.: The mammary pathology of genetically engineered mice: the consensus report and recommendations from the Annapolis meeting. Oncogene 19(8): 968-988, 2000
68. Jhappan C, Stahle C, Harkins RN, Fausto N, Smith GH, Merlino GT: TGF alpha overexpression in transgenic mice induces liver neoplasia and abnormal development of the mammary gland and pancreas. Cell 61(6): 1137-1146, 1990
69. Matsui Y, Halter SA, Holt JT, Hogan BL, Coffey RJ: Development of mammary hyperplasia and neoplasia in MMTV-TGF alpha transgenic mice. Cell 61(6): 1147-1155, 1990
70. Sandgren EP, Luetteke NC, Palmiter RD, Brinster RL, Lee DC: Overexpression of TGF alpha in transgenic mice: induction of epithelial hyperplasia, pancreatic metaplasia, and carcinoma of the breast. Cell 61(6): 1121-1135, 1990
71. Sandgren EP, Schroeder JA, Qui TH, Palmiter RD, Brinster RL, Lee DC: Inhibition of mammary gland involution is associated with transforming growth factor alpha but not c-myc-induced tumorigenesis in transgenic mice. Cancer Res 55(17): 3915-3927, 1995
72. Rose-Hellekant TA, Sandgren EP: Transforming growth factor alpha- and c-myc-induced mammary carcinogenesis in transgenic mice. Oncogene 19(8): 1092-1096, 2000
73. Krane IM, Leder P: NDF/heregulin induces persistence of terminal end buds and adenocarcinomas in the mammary glands of transgenic mice. Oncogene 12(8): 1781-1788, 1996
74. Slamon DJ, Clark GM: Amplification of c-erbB-2 and aggressive human breast tumors? Science 240(4860): 1795-1798, 1988
75. Slamon DJ, Godolphin W, Jones LA, Holt JA, Wong SG, Keith DE, Levin WJ, Stuart SG, Udove J, Ullrich A, et al.: Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 244(4905): 707-712, 1989
76. Bouchard L, Lamarre L, Tremblay PJ, Jolicoeur P: Stochastic appearance of mammary tumors in transgenic mice carrying the MMTV/c-neu oncogene. Cell 57(6): 931-936, 1989
77. Guy CT, Cardiff RD, Muller WJ: Induction of mammary tumors by expression of polyomavirus middle T oncogene: a transgenic mouse model for metastatic disease. Mol Cell Biol 12(3): 954-961, 1992
78. Guy CT, Cardiff RD, Muller WJ: Activated neu induces rapid tumor progression. J Biol Chem 271(13): 7673-7678, 1996
79. Guy CT, Webster MA, Schaller M, Parsons TJ, Cardiff RD, Muller WJ: Expression of the neu protooncogene in the mammary epithelium of transgenic mice induces metastatic disease. Proc Natl Acad Sci USA 89(22): 10578-10582, 1992
80. Muller WJ, Lee FS, Dickson C, Peters G, Pattengale P, Leder P: The int-2 gene product acts as an epithelial growth factor in transgenic mice. EMBO J 9(3): 907-913, 1990
81. Siegel PM, Dankort DL, Hardy WR, Muller WJ: Novel activating mutations in the neu proto-oncogene involved in induction of mammary tumors. Mol Cell Biol 14(11): 7068-7077, 1994
82. Menard S, Aiello P, Tagliabue E, Rumio C, Lollini PL, Colnaghi MI, Balsari A: Tamoxifen chemoprevention of a hormone-independent tumor in the proto-neu transgenic mice model. Cancer Res 60(2): 273-275, 2000
83. Sacco MG, Soldati S, Indraccolo S, Cato EM, Cattaneo L, Scanziani E, Vezzoni P: Combined antiestrogen, antiangiogenic and anti-invasion therapy inhibits primary and metastatic tumor growth in the MMTVneu model of breast cancer. Gene Ther 10(22): 1903-1909, 2003
84. Kobayashi H, Hamaya E: [Raloxifene hydrochloride (Evista Tablet 60 mg) for postmenopausal osteoporosis: mode of action and clinical efficacy]. Nippon Yakurigaku Zasshi 125(1): 37-48, 2005
85. Noguchi S, Koyama H, Uchino J, Abe R, Miura S, Sugimachi K, Akazawa K, Abe O: Postoperative adjuvant therapy with tamoxifen, tegafur plus uracil, or both in women with node-negative breast cancer: a pooled analysis of six randomized controlled trials. J Clin Oncol 23(10): 2172-2184, 2005
86. Wu K, Zhang Y, Xu XC, Hill J, Celestino J, Kim HT, Mohsin SK, Hilsenbeck SG, Lamph WW, Bissonette R, et al.: The retinoid X receptor-selective retinoid, LGD1069, prevents the development of estrogen receptor-negative mammary tumors in transgenic mice. Cancer Res 62(22): 6376-6380, 2002
87. Howe LR, Brown AM: Wnt signaling and breast cancer. Cancer Biol Ther 3(1): 36-41, 2004
88. Kwan H, Pecenka V, Tsukamoto A, Parslow TG, Guzman R, Lin TP, Muller WJ, Lee FS, Leder P, Varmus HE: Transgenes expressing the Wnt-1 and int-2 proto-oncogenes cooperate during mammary carcinogenesis in doubly transgenic mice. Mol Cell Biol 12(1): 147-154, 1992
89. Nass SJ, Dickson RB: Defining a role for c-Myc in breast tumorigenesis. Breast Cancer Res Treat 44(1): 1-22, 1997
90. Shibata MA, Ward JM, Devor DE, Liu ML, Green JE: Progression of prostatic intraepithelial neoplasia to invasive carcinoma in C3(1)/SV40 large T antigen transgenic mice: histopathological and molecular biological alterations. Cancer Res 56(21): 4894-4903, 1996
91. Stewart TA, Pattengale PK, Leder P: Spontaneous mammary adenocarcinomas in transgenic mice that carry and express MTV/myc fusion genes. Cell 38(3): 627-637, 1984
92. Harris SL, Levine AJ: The p53 pathway: positive and negative feedback loops. Oncogene 24(17): 2899-2908, 2005
93. Elledge RM, Clark GM, Fuqua SA, Yu YY, Allred DC: p53 protein accumulation detected by five different antibodies: relationship to prognosis and heat shock protein 70 in breast cancer. Cancer Res 54(14): 3752-3757, 1994
94. Donehower LA, Harvey M, Slagle BL, McArthur MJ, Montgomery CA, Butel JS Jr, Bradley A: Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumours. Nature 356(6366): 215-221, 1992
95. Li B, Rosen JM, McMenamin-Balano J, Muller WJ, Perkins AS: neu/ERBB2 cooperates with p53-172H during mammary tumorigenesis in transgenic mice. Mol Cell Biol 17(6): 3155-3163, 1997
96. Li Q, Yoshioka N, Yutsudo M, Inafuku S, Aozasa K, Kitamura Y, Aizawa S, Nishimune Y, Hakura A, Kondoh G: Human papillomavirus-induced carcinogenesis with p53 deficiency in mouse: novel lymphomagenesis in HPV16E6E7 transgenic mice mimicking p53 defect. Virology 252(1): 28-33, 1998
97. Green JE, Shibata MA, Yoshidome K, Liu ML, Jorcyk C, Anver MR, Wigginton J, Wiltrout R, Shibata E, Kaczmarczyk S, et al.: The C3(1)/SV40 T-antigen transgenic mouse model of mammary cancer: ductal epithelial cell targeting with multistage progression to carcinoma. Oncogene 19(8): 1020-1027, 2000
98. Maroulakou IG, Anver M, Garrett L, Green JE: Prostate and mammary adenocarcinoma in transgenic mice carrying a rat C3(1) simian virus 40 large tumor antigen fusion gene. Proc Natl Acad Sci USA 91(23): 11236-11240, 1994
99. Dickson C, Fantl V, Gillett C, Brookes S, Bartek J, Smith R, Fisher C, Barnes D, Peters G: Amplification of chromosome band 11q13 and a role for cyclin D1 in human breast cancer. Cancer Lett 90(1): 43-50, 1995
100. Bartkova J, Lukas J, Muller H, Lutzhoft D, Strauss M, Bartek J: Cyclin D1 protein expression and function in human breast cancer. Int J Cancer 57(3): 353-361, 1994
101. Lee RJ, Albanese C, Stenger RJ, Watanabe G, Inghirami G, Haines GK, Webster M 3, Muller WJ, Brugge JS, Davis RJ, et al.: pp60(v-src) induction of cyclin D1 requires collaborative interactions between the extracellular signal-regulated kinase, p38, and Jun kinase pathways. A role for cAMP response element-binding protein and activating transcription factor-2 in pp60(v-src) signaling in breast cancer cells. J Biol Chem 274(11): 7341-7350, 1999
102. Liu CH, Chang SH, Narko K, Trifan OC, Wu MT, Smith E, Haudenschild C, Lane TF, Hla T: Overexpression of cyclooxygenase-2 is sufficient to induce tumorigenesis in transgenic mice. J Biol Chem 276(21): 18563-18569, 2001
103. Daphna-Iken D, Shankar DB, Lawshe A, Ornitz DM, Shackleford GM, MacArthur CA: MMTV-Fgf8 transgenic mice develop mammary and salivary gland neoplasia and ovarian stromal hyperplasia. Oncogene 17(21): 2711-2717, 1998
104. Moody SE, Sarkisian CJ, Hahn KT, Gunther EJ, Pickup S, Dugan KD, Innocent N, Cardiff RD, Schnall MD, Chodosh LA: Conditional activation of Neu in the mammary epithelium of transgenic mice results in reversible pulmonary metastasis. Cancer Cell 2(6): 451-461, 2002
105. Smith GH, Gallahan D, Diella F, Jhappan C, Merlino G, Callahan R: Constitutive expression of a truncated INT3 gene in mouse mammary epithelium impairs differentiation and functional development. Cell Growth Differ 6(5): 563-577, 1995
106. Lin EY, Jones JG, Li P, Zhu L, Whitney KD, Muller WJ, Pollard JW: Progression to malignancy in the polyoma middle T oncoprotein mouse breast cancer model provides a reliable model for human diseases. Am J Pathol 163(5): 2113-2126, 2003
107. Chatterjee G, Rosner A, Han Y, Zelazny ET, Li B, Cardiff RD, Perkins AS: Acceleration of mouse mammary tumor virus-induced murine mammary tumorigenesis by a p53 172H transgene: influence of FVB background on tumor latency and identification of novel sites of proviral insertion. Am J Pathol 161(6): 2241-2253, 2002
108. D'Cruz CM, Gunther EJ, Boxer RB, Hartman JL, Sintasath L, Moody SE, Cox JD, Ha SI, Belka GK, Golant A, et al.: c-MYC induces mammary tumorigenesis by means of a preferred pathway involving spontaneous Kras2 mutations. Nat Med 7(2): 235-239, 2001
109. Smith GH, Sharp R, Kordon EC, Jhappan C, Merlino G: Transforming growth factor-alpha promotes mammary tumorigenesis through selective survival and growth of secretory epithelial cells. Am J Pathol 147(4): 1081-1096, 1995
110. Gallahan D, Jhappan C, Robinson G, Hennighausen L, Sharp R, Kordon E, Callahan R, Merlino G, Smith GH: Expression of a truncated Int3 gene in developing secretory mammary epithelium specifically retards lobular differentiation resulting in tumorigenesis. Cancer Res 56(8): 1775-1785, 1996
111. Schulze-Garg C, Lohler J, Gocht A, Deppert W: A transgenic mouse model for the ductal carcinoma in situ (DCIS) of the mammary gland. Oncogene 19(8): 1028-1037, 2000
112. Hadsell DL, Greenberg NM, Fligger JM, Baumrucker CR, Rosen JM: Targeted expression of des(1-3) human insulin-like growth factor I in transgenic mice influences mammary gland development and IGF-binding protein expression. Endocrinology 137(1): 321-330, 1996
113. Gallego MI, Bierie B, Hennighausen L: Targeted expression of HGF/SF in mouse mammary epithelium leads to metastatic adenosquamous carcinomas through the activation of multiple signal transduction pathways. Oncogene 22(52): 8498-8508, 2003
114. Strange R, Li F, Saurer S, Burkhardt A, Friis RR: Apoptotic cell death and tissue remodelling during mouse mammary gland involution. Development 115(1): 49-58, 1992
115. Lin SC, Lee KF, Nikitin AY, Hilsenbeck SG, Cardiff RD, Li A, Kang KW, Frank SA, Lee WH, Lee EY: Somatic mutation of p53 leads to estrogen receptor alpha-positive and -negative mouse mammary tumors with high frequency of metastasis. Cancer Res 64(10): 3525-3532, 2004
116. Jager R, Herzer U, Schenkel J, Weiher H: Overexpression of Bcl-2 inhibits alveolar cell apoptosis during involution and accelerates c-myc-induced tumorigenesis of the mammary gland in transgenic mice. Oncogene 15(15): 1787-1795, 1997
117. Bates P, Fisher R, Ward A, Richardson L, Hill DJ, Graham CF: Mammary cancer in transgenic mice expressing insulin-like growth factor II (IGF-II). Br J Cancer 72(5): 1189-1193, 1995
118. Bortner DM, Rosenberg MP: Induction of mammary gland hyperplasia and carcinomas in transgenic mice expressing human cyclin E. Mol Cell Biol 17(1): 453-459, 1997
119. Jerry DJ, Kittrell FS, Kuperwasser C, Laucirica R, Dickinson ES, Bonilla PJ, Butel JS, Medina D: A mammary-specific model demonstrates the role of the p53 tumor suppressor gene in tumor development. Oncogene 19(8): 1052-1058, 2000